Table 1.
Baseline Characteristics of HCC Patients Undergoing PA-TACE
| Variable | Entire Population n=165 | Non-Early Recurrence n=94 | Early Recurrence n=71 | p-value |
|---|---|---|---|---|
| Male gender, n(%) | 130(78.8)/35(21.2) | 71(75.5)/23(24.5) | 59(83.1)/12(16.9) | 0.239 |
| Age,(years) | 56.0±9.4 | 55.9±8.9 | 56.0±10.0 | 0.630 |
| Etiology, n(%) | 0.879 | |||
| Hepatitis B virus | 149(90.3) | 85(90.4) | 64(90.1) | |
| Hepatitis C virus | 8(4.8) | 5(5.3) | 3(4.2) | |
| Others | 8(4.8) | 4(4.3) | 4(5.6) | |
| Liver function, n (%) | ||||
| Cirrhosis, | 97(58.8) | 59(62.8) | 38(53.5) | 0.232 |
| Child–Pugh A/B | 130(78.8) | 74(78.7) | 56(78.9) | 0.981 |
| TBIL >14.4 (μmol/L) | 97(58.8) | 57(60.6) | 40(56.3) | 0.578 |
| ALT>40 (IU/L) | 37(22.4) | 17(18.1) | 20(28.2) | 0.124 |
| AST>40 (IU/L) | 34(20.6) | 15(16.0) | 19(26.8) | 0.089 |
| Albumin <40 (g/L) | 66(40.0) | 33(35.1) | 33(46.5) | 0.140 |
| Tumor markers | ||||
| AFP, n (%) | 0.339 | |||
| ≤400 ng/mL | 129(78.2) | 76(80.9) | 53(74.6) | |
| >400 ng/mL | 36(21.8) | 18(19.1) | 18(25.4) | |
| AFP-L3%≥10% | 58(35.2) | 20(21.3) | 38(53.5) | <0.001 |
| Inflammation-associated parameters | ||||
| NLR>3 | 31(18.8) | 16(17.0) | 15(21.1) | 0.504 |
| GLR>20 | 93(56.4) | 44(46.8) | 49(69.0) | 0.004 |
| SII>297 | 82(49.7) | 44(46.8) | 38(53.5) | 0.393 |
| ALRI>12 | 129(78.2) | 67(71.3) | 62(87.3) | 0.013 |
| Pathological characteristics | ||||
| MVI | 0.001 | |||
| M0 | 91(55.2) | 62(66.0) | 29(40.8) | |
| M1+M2 | 74(44.8) | 32(34.0) | 42(59.2) | |
| Edmondson-Steiner | 0.316 | |||
| I+II | 51(29.9) | 32(34.0) | 19(26.8) | |
| III+IV | 114(69.1) | 62(66.0) | 52(73.2) | |
| Ki67 | <0.001 | |||
| >50 | 71(43.0) | 22(23.4) | 49(69.0) | |
| ≤50 | 94(57.0) | 72(76.6) | 22(31.0) |